Access Bio Inc (950130) - Net Assets
Based on the latest financial reports, Access Bio Inc (950130) has net assets worth ₩599.93 Billion KRW (≈ $406.56 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩667.01 Billion ≈ $452.02 Million USD) and total liabilities (₩67.08 Billion ≈ $45.46 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Access Bio Inc's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩599.93 Billion |
| % of Total Assets | 89.94% |
| Annual Growth Rate | -27.71% |
| 5-Year Change | 474.77% |
| 10-Year Change | -99.42% |
| Growth Volatility | 33231.55 |
Access Bio Inc - Net Assets Trend (2012–2024)
This chart illustrates how Access Bio Inc's net assets have evolved over time, based on quarterly financial data. See 950130 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Access Bio Inc (2012–2024)
The table below shows the annual net assets of Access Bio Inc from 2012 to 2024. For live valuation and market cap data, see how much is Access Bio Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩442.28 Million ≈ $299.73K |
-99.92% |
| 2023-12-31 | ₩587.14 Billion ≈ $397.90 Million |
+120280.16% |
| 2022-12-31 | ₩487.74 Million ≈ $330.53K |
+101.76% |
| 2021-12-31 | ₩241.75 Million ≈ $163.83K |
+214.16% |
| 2020-12-31 | ₩76.95 Million ≈ $52.15K |
+262.64% |
| 2019-12-31 | ₩21.22 Million ≈ $14.38K |
-36.51% |
| 2018-12-31 | ₩33.42 Million ≈ $22.65K |
-18.73% |
| 2017-12-31 | ₩41.13 Million ≈ $27.87K |
-13.50% |
| 2016-12-31 | ₩47.55 Million ≈ $32.22K |
-99.94% |
| 2015-12-31 | ₩76.88 Billion ≈ $52.10 Million |
+12.10% |
| 2014-12-31 | ₩68.58 Billion ≈ $46.48 Million |
+36.63% |
| 2013-12-31 | ₩50.20 Billion ≈ $34.02 Million |
+131.25% |
| 2012-12-31 | ₩21.71 Billion ≈ $14.71 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Access Bio Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2600.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩440.23 Million | 99.54% |
| Common Stock | ₩1.90 Million | 0.43% |
| Other Components | ₩147.84K | 0.03% |
| Total Equity | ₩442.28 Million | 100.00% |
Access Bio Inc Competitors by Market Cap
The table below lists competitors of Access Bio Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
K2 Gold Corporation
V:KTO
|
$125.44 Million |
|
Spring Valley Acquisition Corp. II Class A Ordinary Shares
NASDAQ:SVII
|
$125.48 Million |
|
China National Accord Medicines Corp Ltd
SHE:200028
|
$125.51 Million |
|
Avaco Co. Ltd
KQ:083930
|
$125.52 Million |
|
Caisse Régionale du Crédit Agricole Alpes Provence
PA:CRAP
|
$125.38 Million |
|
Igis Value Plus Reit Co Ltd
KO:334890
|
$125.36 Million |
|
Business Online PCL
BK:BOL
|
$125.31 Million |
|
Arihant Superstructures Limited
NSE:ARIHANTSUP
|
$125.28 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Access Bio Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 584,155,184,000 to 442,280,350, a change of -583,712,903,650 (-99.9%).
- Net loss of 254,830 reduced equity.
- Other factors decreased equity by 583,712,648,820.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-254.83K | -0.06% |
| Other Changes | ₩-583.71 Billion | -131977.97% |
| Total Change | ₩- | -99.92% |
Book Value vs Market Value Analysis
This analysis compares Access Bio Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 418.32x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2965.03x to 418.32x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1.77 | ₩5260.00 | x |
| 2017-12-31 | ₩1.56 | ₩5260.00 | x |
| 2018-12-31 | ₩1.27 | ₩5260.00 | x |
| 2019-12-31 | ₩0.65 | ₩5260.00 | x |
| 2020-12-31 | ₩2.16 | ₩5260.00 | x |
| 2021-12-31 | ₩6.79 | ₩5260.00 | x |
| 2022-12-31 | ₩14.36 | ₩5260.00 | x |
| 2023-12-31 | ₩17302.39 | ₩5260.00 | x |
| 2024-12-31 | ₩12.57 | ₩5260.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Access Bio Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.06%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -0.31%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 1.14x
- Recent ROE (-0.06%) is below the historical average (8.96%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.55% | 0.94% | 0.31x | 1.92x | ₩-4.49 Million |
| 2017 | -13.95% | -22.01% | 0.30x | 2.12x | ₩-9.85 Million |
| 2018 | -11.53% | -10.54% | 0.43x | 2.54x | ₩-7.20 Million |
| 2019 | -71.11% | -40.85% | 0.61x | 2.84x | ₩-17.21 Million |
| 2020 | 53.16% | 39.63% | 0.66x | 2.03x | ₩33.21 Million |
| 2021 | 68.56% | 37.55% | 1.18x | 1.54x | ₩141.58 Million |
| 2022 | 55.02% | 33.53% | 1.15x | 1.43x | ₩219.56 Million |
| 2023 | 0.00% | -0.91% | 0.00x | 1.18x | ₩-58.42 Billion |
| 2024 | -0.06% | -0.31% | 0.16x | 1.14x | ₩-44.48 Million |
Industry Comparison
This section compares Access Bio Inc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $85,995,631,421
- Average return on equity (ROE) among peers: -61.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Access Bio Inc (950130) | ₩599.93 Billion | 0.55% | 0.11x | $125.38 Million |
| NSN Co. Ltd (031860) | $24.50 Billion | 0.00% | 0.45x | $12.68 Million |
| JOONGANG DNM Co.Ltd (051980) | $36.75 Billion | -46.84% | 0.41x | $96.54 Million |
| GeneMatrix Inc (109820) | $12.78 Billion | 0.00% | 0.54x | $23.34 Million |
| Genoray Co. Ltd (122310) | $59.59 Billion | 22.22% | 0.32x | $28.57 Million |
| Green Cross Lab Cell Corporation (144510) | $541.48 Billion | -0.03% | 0.23x | $172.92 Million |
| Optipharm.CO.LTD (153710) | $12.79 Billion | -12.25% | 0.55x | $46.58 Million |
| Cytogen Inc (217330) | $2.66 Billion | -143.13% | 0.60x | $62.61 Million |
| Gencurix Inc (229000) | $6.48 Billion | -379.86% | 4.75x | $25.18 Million |
| P&K Skin Research Center Co. Ltd (347740) | $76.94 Billion | 7.56% | 0.07x | $37.29 Million |
About Access Bio Inc
Access Bio, Inc. engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide. The company provides Covid-19 detection kits, which are tests for assessing the current or past presence of SARS-CoV-2.; rapid diagnostic tests, suitable for preliminary diagnosis or emergency medical screening in medical facilities wi… Read more